This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo


Cream containing 10% crotamiton
Topical emulsion containing 10% crotamiton

Drugs List

  • crotamiton 10% cream
  • EURAX cream
  • Therapeutic Indications


    Relief of pruritus caused by, for example sunburn, dry eczema, itchy dermatitis, allergic rashes, hives, nettle rash, chickenpox, insect bites and stings, heat rashes and personal itching.

    Treatment of scabies.



    Apply to the affected area two or three times daily.
    Each application should provide relief from itching for 6 to 10 hours.

    After the patient has taken a warm bath, the skin should be well dried and the crotamiton cream or emulsion rubbed into the entire body surface (excluding the face and scalp) until no traces of the preparation remain visible on the surface.

    The application should be repeated once daily, preferably in the evening, for a total of three to five days.

    Depending on response, special attention should be paid to sites that are particularly susceptible to infestation (wrists, interdigital spaces, axillae and genitalia).
    Areas where there is pus formation should be covered with a dressing impregnated with crotamiton.
    While the treatment is in progress the patient may take a bath shortly before the next application.
    Once treatment is complete, a cleansing bath should be taken followed by a change of bed linen and underclothing.


    Children aged 3 to 18 years
    Apply to the affected area two or three times daily.

    The manufacturer suggests that crotamiton cream and emulsion can be used in children but does not specify a dose.

    Children aged under 3 years
    To be used under medical supervision.
    Apply to the affected area once daily.

    Apply to the affected area once daily.


    For topical administration


    Acute exudative dermatoses

    Precautions and Warnings

    Consult doctor before use on children under 3 years - see Dosage: Children.

    Do not use in or around the eyes, on broken skin or for weeping skin conditions.

    Genital pruritus - consult doctor before use.

    Discontinue if hypersensitivity reactions occur.

    Pregnancy - see Pregnancy section .

    Breastfeeding - see Lactation section.

    Pregnancy and Lactation


    There is no experience to judge the safety of crotamiton in pregnancy, therefore manufacturer does not recommend its use during pregnancy, especially in the first 3 months.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14-17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password at ( ) or if this is unavailable at the backup site ( ).


    It is not known whether the active substance passes into breast milk so caution in use is required.

    Nursing mothers should avoid application to the nipple area.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Effects on Ability to Drive and Operate Machinery

    None known


    Patients should be advised to contact their doctor if symptoms persist.

    Side Effects

    Local irritation
    Contact allergy


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Shelf Life and Storage

    Protect from heat

    Reference Sources

    Summary of Product Characteristics: Eurax Cream. Novartis Consumer Health. Revised April 2004.
    Summary of Product Characteristics: Eurax Lotion. Novartis Consumer Health. Revised November 2001.

    NICE Evidence Services Available at: Last accessed: 06 September 2017

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.